Pediatric Clinical Trials Market to grow with a CAGR of 7.50%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Pediatric Clinical Trials Market.
According
to TechSci Research report, “Global Pediatric Clinical Trials Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Pediatric Clinical
Trials Market has valued at USD 14.70 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 7.50% through
2028. This can be due to collaborations and partnerships among leading companies
with a diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
The
globalization of clinical trials is a driver for the global pediatric clinical
trials market. The globalization of clinical trials refers to the practice of
conducting clinical research in multiple countries or regions outside the
sponsor's home country. Conducting clinical trials on a global scale allows
researchers to access diverse patient populations, including children from
different ethnic backgrounds and geographic regions. This diversity is crucial
for understanding how treatments may vary across populations and for
generalizing trial results. Globalization increases the pool of potential
pediatric participants, which is particularly important for rare diseases or
conditions that affect only a small number of children in any single region. A
larger participant pool can expedite patient recruitment. Enrolling
participants in pediatric clinical trials can be challenging due to the limited
number of eligible patients at a single site or country. Globalization can help
accelerate recruitment and reduce the time required to complete trials. Conducting
trials in different countries or regions allows researchers to observe how
treatments perform in various healthcare settings, including academic medical
centers, community hospitals, and clinics. This diversity enhances the
generalizability of trial results.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Pediatric Clinical Trials Market”
Children
are a unique demographic with significant physiological and developmental
differences from adults. Clinical trials in children are essential to develop
age-specific, empirically validated drugs and therapies as well as to determine
and improve the best medical care currently available. Clinical studies
involving children are essential because they help identify the best pediatric
preventative measures. Children go through a variety of physiological processes
as they develop from infancy through adolescence and adulthood. They are not
merely little adults. As a result of the differences in how children's bodies
function from adults', pediatric-specific drugs and preventatives must be
developed rather than just modifying adult dosages and therapies for children.
In
July 2022, A Phase 3 trial evaluating the investigational use of Dupixent
(dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE)
met its primary endpoint of histological disease remission at 16 weeks with
both higher and lower dose weight-tiered regimens, according to a press release
from Regeneron Pharmaceuticals, Inc., and Sanofi. For kids under the age of 12,
there are no recognized treatments for EoE. EoE is a chronic inflammatory
condition that harms the oesophagus and impairs its functionality. Dupixent's
effects on adults and kids with EoE show that IL-4 and IL-13 are important
regulators of the type 2 inflammation that underlies this condition. Children
with eosinophilic esophagitis frequently have acid reflux, vomiting, stomach
pain, difficulty swallowing, and failure to thrive. These symptoms may have an
adverse effect on growth and development as well as lead to a dread of food
that may last into adulthood.
The lack of pediatric expertise is a significant challenge
in the global pediatric clinical trials market. This challenge manifests in
several ways and can impact the planning, execution, and success of pediatric
clinical trials.
Pediatric clinical trials require specialized
knowledge of pediatric medicine, including the unique physiological and
developmental differences in children compared to adults. Lack of expertise in
pediatric healthcare can lead to difficulties in designing appropriate trial
protocols and understanding the specific needs of pediatric participants. Determining
appropriate dosing regimens for pediatric patients is complex due to
age-related variations in drug metabolism, body weight, and developmental
stages. Pediatric experts are crucial for calculating and adjusting dosages to
ensure safety and efficacy.
Pediatric trials must have expertise in managing
adverse events and side effects that may be unique to children. Understanding
the signs, symptoms, and appropriate interventions for pediatric adverse events
is essential.
Global Pediatric Clinical Trials Market segmentation
is based on phase, study design, therapeutic area, region and company
Based on study design, Global Pediatric Clinical
Trials Market is segmented into Treatment Studies and Observational Studies. Observational
studies in pediatric clinical trials are research investigations in which
researchers observe and collect data from pediatric patients without
intervening or administering specific treatments. These studies are designed to
gain insights into various aspects of pediatric health, disease, and treatment
outcomes by observing patients in their natural clinical settings. The primary
objective of observational studies is to gather real-world data on pediatric
patients' characteristics, behaviors, treatments, or outcomes over time. These
studies aim to understand patterns, associations, and trends within the
observed population.
Unlike interventional clinical trials,
observational studies do not involve administering experimental treatments or
interventions to participants. Instead, researchers observe and document what
occurs naturally during routine clinical care.
Based on Region, North America dominated the Global Pediatric Clinical
Trials Market. The United States invests heavily in research and
development (R&D), which includes funding for pediatric clinical trials.
Government agencies, private foundations, and industry players contribute to
this funding. North America represents a lucrative market for pediatric drugs
due to its large population and high healthcare spending. This market
attractiveness incentivizes pharmaceutical companies to invest in pediatric
clinical trials to gain regulatory approvals. The region has made significant
advancements in pediatric medicine and research, which further strengthens its
position in the global pediatric clinical trials market.
Asia-pacific region to fastest growth in
the Global Pediatric Clinical Trials Market. The Asia-Pacific region has a
substantial pediatric population, including infants, children, and adolescents.
This large and diverse population provides a significant pool of potential
participants for pediatric clinical trials. The prevalence of pediatric
diseases and health issues is rising in the Asia-Pacific region. Factors such as
changing lifestyles, environmental factors, and infectious diseases contribute
to a growing pediatric healthcare burden. This trend drives the demand for
clinical research and innovative treatments. Many pharmaceutical companies and
clinical research organizations recognize the market potential in the
Asia-Pacific region, particularly for pediatric drug development. The region's
growth presents an opportunity to develop and market pediatric medications and
therapies.
Some
of the major companies operating in the Global
Pediatric Clinical Trials Market include:
- Bristol-Myers Squibb Company
- Charles River Laboratories International Inc.
- Covance Inc.
- GlaxoSmithKline plc
- ICON plc
- IQVIA Inc.
- Novartis AG
- Pfizer, Inc.
- Pharmaceutical Product Development, LLC
- Syneos Health Inc.
- Paidion Research, Inc.
- The
Emmes Company, LLC
Download Free Sample Report
Customers can also request
10% free customization on this report
“Certain areas, particularly in
North America, are projected to exert significant demand of drugs. The growth
in the competitive landscape and the presence of well-established companies in
the market, committed to enhance the overall wellbeing of people each year, are
expected to contribute to a remarkable growth of the Global Pediatric Clinical
Trials Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Pediatric
Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented by Phase (Phase I, Phase II, Phase III, and Phase
IV), Study Design (Treatment Studies and Observational Studies), Therapeutic
Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other
Therapeutic Areas), and By Region, Competition evaluated
the future growth potential of Global Pediatric Clinical Trials Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Pediatric Clinical Trials Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com